Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis).
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gargiulo Luigi, Ibba Luciano, Cascio Ingurgio Ruggero, Malagoli Piergiorgio, Amoruso Fabrizio, Balato Anna, Bardazzi Federico, Brianti Pina, Brunasso Giovanna, Burlando Martina, Cagni Anna E, Caproni Marzia, Carrera Carlo G, Carugno Andrea, Caudullo Francesco, Cuccia Aldo, Dapavo Paolo, Di Brizzi Eugenia V, Dini Valentina, Gaiani Francesca M, Gisondi Paolo, Guarneri Claudio, Lasagni Claudia, Licata Gaetano, Loconsole Francesco, Marzano Angelo V, Megna Matteo, Mercuri Santo R, Musumeci Maria L, Orsini Diego, Ribero Simone, Ruffo Di Calabria Valentina, Satolli Francesca, Strippoli Davide, Travaglini Massimo, Trovato Emanuele, Venturini Marina, Zichichi Leonardo, Valenti Mario, Costanzo Antonio, Narcisi Alessandra
Аннотация
MATERIALS AND METHODS: Our retrospective study included 134 patients treated with tildrakizumab 200 mg and 364 patients treated with tildrakizumab 100 mg from 28 Italian Dermatology Units affected by moderate-to-severe plaque psoriasis. The patients had a body weight above 90 kg or a high disease burden (Psoriasis Area and Severity Index [PASI] ≥ 16 or the involvement of difficult-to-treat areas). We evaluated the effectiveness of tildrakizumab at the week-16 visit in terms of PASI90, PASI100 and absolute PASI ≤ 2.
RESULTS: After 16 weeks of treatment with tildrakizumab 200 mg, PASI90 was reached by 57.5% of patients and PASI100 by 39.6% of patients. At the same time point, 34.3% and 24.2% of patients treated with tildrakizumab 100 mg achieved PASI90 and PASI100, respectively.
CONCLUSIONS: Our data suggest that tildrakizumab 200 mg has better effectiveness than tildrakizumab 100 mg in patients with a body weight ≥ 90 kg and a high disease burden.